Anti-inflammatory Compound Development For The Treatment Of Heart Failure With Preserved Ejection Fraction
Funder
National Health and Medical Research Council
Funding Amount
$674,659.00
Summary
Heart failure with preserved ejection fraction (HFpEF) is a highly prevalent and rapidly growing heart condition with no proven effective therapies. We will develop novel drugs to treat HFpEF by focussing on heart scarring and inflammation. We have promising drug candidates that will be developed during the project, and these will be ready for for phase I clinical trial by the end of this grant. The outcome of this study is poised to address the significant unmet medical need.
A Non-invasive Fluid Status Monitoring Device For Heart Failure
Funder
National Health and Medical Research Council
Funding Amount
$360,715.00
Summary
Both acute decompensated heart failure (ADHF) and chronic kidney disease (CKD) are characterised by fluid overload. A device to detect this fluid overload in patients at an early stage has the potential to reduce the need for hospitalisation and initiate more timely and aggressive intervention. A prototype device has already been developed and our aim is to further improve on this device and advance to a commercial product.
Development Of An Extended Release Oral Formulation Of Milrinone For Patients With Advanced Heart Failure
Funder
National Health and Medical Research Council
Funding Amount
$467,083.00
Summary
Heart failure is a debilitating condition associated with frequent hospitalization. Milrinone is an effective intravenous drug used to treat acute deteriorations. Previously, oral milrinone failed because of the lack of availability of appropriate formulations. We have developed an oral formulation which provides stable release of the medication. This application will evaluate the effectiveness of the drug in man and provide the documentation to take the project forward for partnership with indu ....Heart failure is a debilitating condition associated with frequent hospitalization. Milrinone is an effective intravenous drug used to treat acute deteriorations. Previously, oral milrinone failed because of the lack of availability of appropriate formulations. We have developed an oral formulation which provides stable release of the medication. This application will evaluate the effectiveness of the drug in man and provide the documentation to take the project forward for partnership with industry as a means to clinical translation.Read moreRead less
Development Of A First-in-class Therapeutic For Protecting The Ischemic Heart
Funder
National Health and Medical Research Council
Funding Amount
$926,673.00
Summary
Heart disease is the leading cause of death globally. Heart attacks are the primary cause of death associated with heart disease. We have discovered a drug, Hi1a, that blocks the injury response of the heart when a heart attack happens. There are no other drugs currently available or in the discovery pipeline that address this problem. This proposal will use models of injury to the heart as well as safety studies to help develop Hi1a as a new drug for people who suffer from heart attacks.
A Fully Implantable Self Powered Extra Aortic Counterpulsation Device? For Translational Development In Hypertensive Heart Failure
Funder
National Health and Medical Research Council
Funding Amount
$901,586.00
Summary
The development of a low cost self-powered cardiac aortic assist device to improve blood flow to the heart and rest of the body. The device is placed on the external surface of the large blood vessel (aorta) leaving the heart and provides gentle counterpulsation to improve blood flow. This aortic cardiac assist device is a therapeutic treatment for early stage heart failure.
Developing A Safe Vaccine Against Group A Streptococci
Funder
National Health and Medical Research Council
Funding Amount
$768,530.00
Summary
Group A streptococcus causes 520,000 deaths each year. A safe and effective vaccine is not commercially available. We have identified new protective candidate antigens, and we seek to undertake critical non-human primate studies to provide further proof-of-concept data. This work will underpin commercial decisions by our industry partner (Sanofi Pasteur) leading to human trials and the development of a safe group A streptococcal vaccine for human use.
Media Formulations To Enhance Embryo Formation In Assisted Reproduction
Funder
National Health and Medical Research Council
Funding Amount
$660,133.00
Summary
The increasing age of parenthood has led to an explosion in the demand for assisted reproductive technologies such as in vitro fertilisation (IVF). This procedure has a poor success rate and is limited by the ability of fertilised eggs to mature into early embryos in the lab prior to being transferred into women. We will develop new compounds that improve embryo growth in the clinic, which will improve IVF success rates.
Development Of A Novel Microfluidic Device To Treat Male Infertility
Funder
National Health and Medical Research Council
Funding Amount
$508,397.00
Summary
This research aims to develop a novel technology for the separation of high quality sperm. It is envisaged this will replace existing technology to improve the reproductive outcomes of both humans, as well as animals.
Nicotinamide Adenine Dinucleotide (NAD+)-raising Agents For Improving Oocyte Quality
Funder
National Health and Medical Research Council
Funding Amount
$445,827.00
Summary
Many women cannot have children because of suboptimal egg quality, often due to aging. Currently, the only option is to use better quality eggs donated from another woman. This project will use pharmacological agents to promote recently discovered pathways in eggs central to determining quality. Importantly, we will investigate a simple and practical approach that can be used in clinics for augmenting these pathways to improve oocyte quality for the first time.
Infertility is common and although IVF is widely accepted, the procedure is expensive and is associated with health risks. Using laboratory animals, we have made significant advances towards developing new technologies that can mature eggs and produce embryos in vitro, but without women receiving hormone injections. This project will seek means to combine the benefits of two of our existing technologies into one integrated system, to provide hormone-free infertility treatment.